Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

341. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. Full Text available with Trip Pro

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death.We randomly assigned adult patients with severe sepsis and a low risk of death (defined by an Acute Physiology and Chronic Health (...) with an increased incidence of serious bleeding complications, indicates that DrotAA should not be used in patients with severe sepsis who are at low risk for death, such as those with single-organ failure or an APACHE II score less than 25.Copyright 2005 Massachusetts Medical Society.

2005 NEJM Controlled trial quality: predicted high

342. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. Full Text available with Trip Pro

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity.To describe adverse events associated with adjuvant chemotherapy for breast cancer, which led to premature termination of a clinical trial.We conducted a prospective randomized multicenter study (Reposant sur des Arguments Pronostiques et Predictifs [RAPP]-01) to compare

2005 JAMA Controlled trial quality: uncertain

343. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults (...) )) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technology Assessment 2005; 9(11): 1-140 Authors' objectives The aim of this study was to assess the clinical and cost-effectiveness of drotrecogin alfa (activated) for the treatment of adults with severe sepsis in a UK context. Authors' conclusions Drotrecogin alfa (activated) plus best supportive care appears clinically and cost-effective compared with best supportive care alone, in a UK cohort of severe sepsis

2005 Health Technology Assessment (HTA) Database.

344. Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis Full Text available with Trip Pro

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis Macias W L, Nelson D R, Williams M, Garg R, Janes J, Sashegyi A CRD summary This review assessed the evidence for a relationship between treatment efficacy (...) and disease severity in patients with severe sepsis. The authors concluded that there is no evidence to support a relationship between the severity of disease and the effect of treatment on mortality. Poor reporting and a limited search mean it is not possible to determine the reliability of the conclusions. Authors' objectives To determine whether a relationship exists between the mortality risk of a patient population and the benefit of interventions for severe sepsis. Searching PubMed was searched

2005 DARE.

345. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic (...) review and economic evaluation Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson B H CRD summary This review concluded that drotrecogin alfa (activated) is likely to be clinically effective and cost-effective for the treatment of patients with severe sepsis within the UK National Health Service. The review was well conducted and the conclusions are likely to be reliable, although evidence of the treatment's effectiveness came primarily from one large clinical trial

2005 DARE.

346. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden

Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden Hjelmgren J, Persson U, Tennvall G (...) Cost-utility analysis and cost-effectiveness analysis. Study population The study population comprised patients with severe sepsis. Setting The study setting was secondary care. The economic study was carried out in Sweden. Dates to which data relate The effectiveness data were derived from a study published in 2001. The price year was 2002. Source of effectiveness data The effectiveness data were derived from the PROWESS trial (Bernard et al. 2001, see 'Other Publications of Related Interest

2005 NHS Economic Evaluation Database.

347. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Full Text available with Trip Pro

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus D C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two treatment strategies for severe sepsis in patients with multiple organ failure were compared, drotrecogin alfa (activated) and placebo (best usual care). Drotrecogin alfa (activated) was supplied in 5-mg vials and was administered as a 96-hour intravenous infusion of 24 microg/kg per hour. Type

2005 NHS Economic Evaluation Database.

348. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock

Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

349. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.

Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2005 PedsCCM Evidence-Based Journal Club

350. Systemic Inflammatory Response and Progression to Severe Sepsis in Critically Ill Infected Patients.

Systemic Inflammatory Response and Progression to Severe Sepsis in Critically Ill Infected Patients. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2005 PedsCCM Evidence-Based Journal Club

351. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. (Abstract)

Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Previous experimental studies have suggested that the triggering receptor expressed on myeloid cells-1 (TREM-1) is specifically upregulated in the presence of microbial products.To evaluate the diagnostic value of plasma levels of the soluble form of TREM-1 in patients admitted with clinical suspicion of infection.Prospective, noninterventional study conducted between (...) inflammatory response syndrome, sepsis, severe sepsis, or septic shock.The systemic inflammatory response syndrome was diagnosed in 29 patients (38%), and sepsis, severe sepsis, or septic shock was diagnosed in the remaining 47 (62%). A plasma soluble TREM-1 level higher than 60 ng/mL was more accurate than any other clinical or laboratory finding for indicating infection (sensitivity, 96% [95% CI, 92% to 100%]; specificity, 89% [CI, 82% to 95%]; positive likelihood ratio, 8.6 [CI, 3.8 to 21.5]; negative

2004 Annals of Internal Medicine

352. Drug intervention trials in sepsis: divergent results. (Abstract)

Drug intervention trials in sepsis: divergent results. Important advances have been made in our understanding of severe sepsis. Outcome can be improved by targeted interventions, including early and appropriate antibiotic therapy and goal-directed resuscitation, and might be further improved by selective decontamination of the digestive tract, tight control of glucose, and possibly by giving corticosteroids to selected patients. Drugs that target specific steps in the septic cascade include (...) than those even in the most successful trial with an antisepsis agents, underscoring the importance of basic measures in severe sepsis. WHERE NEXT? Initial management in severe sepsis should include early goal-directed fluid resuscitation, appropriate antibiotic treatment, and surgical-site control. Intensive-care units should be run by specialists, with adequate medical and nursing staffing. Tight regulation of glucose, selective decontamination of the digestive tract, and moderate-dose

2004 Lancet

353. Corticosteroids for treating severe sepsis and septic shock. (Abstract)

Corticosteroids for treating severe sepsis and septic shock. Sepsis may be complicated by impaired corticosteroid production. Giving corticosteroids could potentially benefit patients.To examine the effects of corticosteroids on death at one month in patients with severe sepsis and septic shock.We searched the Cochrane Infectious Diseases Group's trial register (August 2003), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2003), MEDLINE (August 2003 (...) ), EMBASE (August 2003), LILACS (August 2003), reference lists of articles, and also contacted trial authors.Randomized and quasi-randomized controlled trials of corticosteroids versus placebo or supportive treatment in severe sepsis and septic shock.Two pairs of reviewers agreed the eligibility of trials. One reviewer extracted data, which was checked by the other reviewers and the primary author of the paper whenever possible. We obtained some missing data from the trial authors. We assessed trial

2004 Cochrane

354. Drotrecogin alfa (activated) for severe sepsis (TA84)

Drotrecogin alfa (activated) for severe sepsis (TA84) Drotrecogin alfa (activated) for severe sepsis | Guidance | NICE Drotrecogin alfa (activated) for severe sepsis Technology appraisal guidance [TA84] Published date: 22 September 2004 Guidance November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint (...) of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis. Explore © NICE [year]. All rights reserved. Subject to .

2004 National Institute for Health and Clinical Excellence - Technology Appraisals

355. Drotrecogin alfa (activated) for severe sepsis

Drotrecogin alfa (activated) for severe sepsis Drotrecogin alfa (activated) for severe sepsis Drotrecogin alfa (activated) for severe sepsis National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Drotrecogin alfa (activated) for severe sepsis. National Institute for Clinical (...) Excellence (NICE). Technology Appraisal Guidance 84. 2004 Authors' objectives To provide guidance on the use of drotrecogin alfa (activated) for severe sepsis. Authors' conclusions Guidance 1.1 Drotrecogin alfa (activated) is recommended for use in adult patients who have severe sepsis that has resulted in multiple organ failure (that is, two or more major organs have failed) and who are being provided with optimum intensive care support. 1.2 The use of drotrecogin alfa (activated) should only

2004 Health Technology Assessment (HTA) Database.

356. Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis

Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis Catalan Agency for Health Technology Assessment and Research Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Catalan Agency for Health Technology Assessment and Research. Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). Technical Assessment. 2004

2004 Health Technology Assessment (HTA) Database.

357. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis

Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2004 PedsCCM Evidence-Based Journal Club

358. The epidemiology of sepsis in the United States from 1979 through 2000. Full Text available with Trip Pro

The epidemiology of sepsis in the United States from 1979 through 2000. Sepsis represents a substantial health care burden, and there is limited epidemiologic information about the demography of sepsis or about the temporal changes in its incidence and outcome. We investigated the epidemiology of sepsis in the United States, with specific examination of race and sex, causative organisms, the disposition of patients, and the incidence and outcome.We analyzed the occurrence of sepsis from 1979 (...) through 2000 using a nationally representative sample of all nonfederal acute care hospitals in the United States. Data on new cases were obtained from hospital discharge records coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification.Review of discharge data on approximately 750 million hospitalizations in the United States over the 22-year period identified 10,319,418 cases of sepsis. Sepsis was more common among men than among women (mean annual

2003 NEJM

359. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? (Abstract)

A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Despite the advances in supportive care and the availability of potent antimicrobial agents, mortality from sepsis, a leading cause of death in intensive care units, has not improved. Over the last decade, clinical trials with numerous adjunctive therapies, including antiendotoxin antibodies and inhibitors of the inflammatory response, have yielded disappointing results. Recently, treatment with recombinant (...) human activated protein C reduced mortality 6% compared with controls. Given the likelihood that many processes in the complex pathophysiology of sepsis are simultaneously activated, it is unlikely that therapy directed at any one of them, as has been done in the past, will dramatically improve survival. Rather, a combination of therapies directed at many arms of the septic process, much like the strategy used for cancer and HIV infection, is required. Given the likelihood that sepsis represents

2003 Annals of Internal Medicine

360. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. (Abstract)

Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Neonatal sepsis causes significant neonatal mortality and morbidity. Neonates, especially preterm infants, have an immaturity of granulopoeisis and have a limited capacity for progenitor cell proliferation. This results in the frequent occurrence of neutropaenia in septic neonates. Neutropaenic septic neonates have a higher mortality than neonates who are septic but not neutropaenic. Transfusion (...) of granulocytes to septic neutropaenic neonates, therefore, may help reduce mortality and morbidity.The primary objective of this review was to determine the efficacy and safety of granulocyte preparations (granulocyte and buffy coat transfusions) as adjuncts to antibiotics for the treatment of confirmed or suspected sepsis in neonates with neutropaenia in reducing all-cause mortality during hospital stay and adverse neurological outcome at a year of age or later. Secondary objectives were to determine

2003 Cochrane